Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance).

@article{Lorusso1999PharmacokineticsAT,
  title={Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance).},
  author={Vito Lorusso and T Arbughi and Piero Tirone and Christoph de Ha{\"e}n},
  journal={Journal of computer assisted tomography},
  year={1999},
  volume={23 Suppl 1},
  pages={
          S181-94
        }
}
OBJECTIVE Evaluation of the pharmacokinetic behavior of gadobenate dimeglumine, a new multipurpose parenteral contrast agent for magnetic resonance imaging. METHODS The pharmacokinetics were evaluated in rats, rabbits, dogs and monkeys after intravenous injections of non-labelled gadobenate dimeglumine and, for biodistribution studies, 153Gd-labelled gadobenate dimeglumine. Assays were performed by high performance liquid chromatography, X-ray fluorescence and gamma spectrometry. The binding… 
Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion
TLDR
Using a nonconventional pharmacokinetic approach, it is shown that gadoterate meglumine undergoes a much faster residual excretion from the body than the linear GBCAs, a process that seems related to the thermodynamic stability of the different chelates.
Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition
TLDR
The biodistribution of approved gadolinium (Gd)‐based contrast agents (GBCAs) is reviewed and very small amounts of Gd are retained in the bone and liver, and the amount retained correlates with the kinetic and thermodynamic stability of the GBCA with respect to Gd release in vitro.
Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats
TLDR
Repeated administrations of the linear GBCAs gadodiamide, gadobenate dimeglumine, and gadopentetate dime glumine to healthy rats were associated with progressive and significant T1 signal hyperintensity in the DCN, along with Gd deposition in the cerebellum.
Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals
TLDR
In a model of renally impaired rats, only traces of gadoterate meglumine were detected in the brain with no T1 hyperintensity of the DCNs, whereas marked Gd retention was observed in almost all brain areas after injections of the L-GBCAs, gadobenate dime glumine and gadodiamide.
Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
TLDR
In the liver, the hepatospecific contrast agent Gd-BOPTA enters into hepatocytes likely through the organic anion transporting peptide 1.5 T with a fast gradient-echo T1-weighted MR sequence.
Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration
TLDR
The purpose of this review is to highlight what is currently known in the literature regarding the pharmacokinetics of gadolinium in humans and animals, and any toxicity associated with GBCA use.
Small Brain Lesion Enhancement and Gadolinium Deposition in the Rat Brain: Comparison Between Gadopiclenol and Gadobenate Dimeglumine.
TLDR
After repeated IV injections, as expected for a macrocyclic GBCA, Gd retention is minimalized in the case of gadopiclenol compared with gadobenate dimeglumine, resulting in no T1 hypersignal in the DCN.
Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents
TLDR
Increased signal intensity in the CN was found up to 24 days after multiple, extended doses of linear GBCAs, however, in contrast to clinical reports, the signal enhancement in the GP was not reproduced, demonstrating the limitations of this animal experiment.
...
1
2
3
4
5
...